Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Colon cancer (CC) pathological staging fails to accurately predict recurrence, and to date, no gene expression signature has proven reliable for prognosis stratification in clinical practice, perhaps because CC is a heterogeneous disease. The aim of this study was to establish a comprehensive molecular classification of CC based on mRNA expression profile analyses. METHODS AND FINDINGS: Fresh-frozen primary tumor samples from a large multicenter cohort of 750 patients with stage I to IV CC who underwent surgery between 1987 and 2007 in seven centers were characterized for common DNA alterations, including BRAF, KRAS, and TP53 mutations, CpG island methylator phenotype, mismatch repair status, and chromosomal instability status, and were screened with whole genome and transcriptome arrays. 566 samples fulfilled RNA quality requirements. Unsupervised consensus hierarchical clustering applied to gene expression data from a discovery subset of 443 CC samples identified six molecular subtypes. These subtypes were associated with distinct clinicopathological characteristics, molecular alterations, specific enrichments of supervised gene expression signatures (stem cell phenotype-like, normal-like, serrated CC phenotype-like), and deregulated signaling pathways. Based on their main biological characteristics, we distinguished a deficient mismatch repair subtype, a KRAS mutant subtype, a cancer stem cell subtype, and three chromosomal instability subtypes, including one associated with down-regulated immune pathways, one with up-regulation of the Wnt pathway, and one displaying a normal-like gene expression profile. The classification was validated in the remaining 123 samples plus an independent set of 1,058 CC samples, including eight public datasets. Furthermore, prognosis was analyzed in the subset of stage II-III CC samples. The subtypes C4 and C6, but not the subtypes C1, C2, C3, and C5, were independently associated with shorter relapse-free survival, even after adjusting for age, sex, stage, and the emerging prognostic classifier Oncotype DX Colon Cancer Assay recurrence score (hazard ratio 1.5, 95% CI 1.1-2.1, p = 0.0097). However, a limitation of this study is that information on tumor grade and number of nodes examined was not available. CONCLUSIONS: We describe the first, to our knowledge, robust transcriptome-based classification of CC that improves the current disease stratification based on clinicopathological variables and common DNA markers. The biological relevance of these subtypes is illustrated by significant differences in prognosis. This analysis provides possibilities for improving prognostic models and therapeutic strategies. In conclusion, we report a new classification of CC into six molecular subtypes that arise through distinct biological pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Summary of the main characteristics of the six subtypes. Symbols correspond to the relative frequency within the subtype (o: very low frequencies [∼0%]; +++: very high frequencies; +/++: intermediate frequencies), and arrows indicate significant enrichment of subtype up- and down-regulated genes in most of the pathways of the given category. EMT, epithelial–mesenchymal transition; SC, stem cell; Wnt pw, Wnt pathway.](https://figures.cochat.ai/paper-figures/d9e6ea3312ee4d83b17b55c403c90fdb/gene-expression-classification-of-colon-cancer-into-molecular-subtypes-figure-3.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Again, the MEKi bypass resistance was strongly correlated with the SRC activation/dasatinib sensitivity, the EMT-like stemness and the CMS4 subtype (see Fig. 6 and Fig. 7 as well as Additional File 3_Fig S5 and Fig S6).”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Similar results were seen in Marisa 458 CMS1-4 CRC tumors (Fig. 8d).”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Edge, S. B., & Compton, C. C. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0985-4 · Cited by 9,029
Adjusting batch effects in microarray expression data using empirical Bayes methods
Johnson, W. E., Li, C., & Rabinovic, A. (2007) · Biostatistics · doi:10.1093/biostatistics/kxj037 · Cited by 8,658
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Summaries of Affymetrix GeneChip probe level data
Irizarry, R. A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng015 · Cited by 4,887
Boland, C. R., Thibodeau, S. N., Hamilton, S. R., Sidransky, D., Eshleman, J. R., Burt, R. W., Meltzer, S. J., Rodrı́guez-Bigas, M. A., Fodde, R., Ranzani, G. N., et al. (1998) · PubMed · Cited by 4,087
Greenlee, R. T., Murray, T., Bolden, S., & Wingo, P. A. (2000) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.50.1.7 · Cited by 3,850
Monti, S., Tamayo, P., Mesirov, J., & Golub, T. (2003) · Machine Learning · doi:10.1023/a:1023949509487 · Cited by 2,116 · cited 1×
“To obtain a robust classification, we used a consensus unsupervised approach [22] implemented in the R package ConsensusClusterPlus.”
MethodWeisenberger, D. J., Siegmund, K. D., Campan, M., Young, J., Long, T. I., Faasse, M. A., Kang, G. H., Widschwendter, M., Weener, D., Buchanan, D., et al. (2006) · Nature Genetics · doi:10.1038/ng1834 · Cited by 1,990
Systematic Review of Microsatellite Instability and Colorectal Cancer Prognosis
Popat, S., Hubner, R., & Houlston, R. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.086 · Cited by 1,830
Research works printed but not linked: 1
- American Joint Committee on Cancer (1997) AJCC cancer staging manual, 5th edition. Philadelphia: Lippincott-Raven.
Cited by
Items 201–300 of 1,001
Long non-coding RNAs in Colorectal Cancer: Progression and Future Directions
Yang, Y. P., Peng, J., Sanjun, C., & Ma, Y. (2017) · Journal of Cancer · doi:10.7150/jca.19794 · Cited by 72
Extracellular Granzyme A Promotes Colorectal Cancer Development by Enhancing Gut Inflammation
Santiago, L., Castro, M., Pamplona, R. S., Garzón-Tituaña, M., Ramírez-Labrada, A., Tapia, E., Moreno, V. R., Layunta, E., Gil‐Gómez, G., Garrido, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107847 · Cited by 72
Allen, W. L., Dunne, P. D., McDade, S., Scanlon, E., Loughrey, M., Coleman, H. G., McCann, C., McLaughlin, K., Nemeth, Z., Syed, N. A., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00241 · Cited by 71
Leveraging Single-Cell Approaches in Cancer Precision Medicine
Nath, A., & Bild, A. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.01.007 · Cited by 72
Precision medicine for metastatic colorectal cancer in clinical practice
Riedesser, J. E., Ebert, M. P. A., & Betge, J. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211072703 · Cited by 71
Colorectal Cancer Classification and Cell Heterogeneity: A Systems Oncology Approach
Blanco, M., Concha, Á., Figueroa, A., Garrido, F., & Valladares‐Ayerbes, M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160613610 · Cited by 72
Effects of Fixation and Storage of Human Tissue Samples on Nucleic Acid Preservation
Nam, S. K., Im, J., Kwak, Y., Han, N., Nam, K. H., Seo, A. N., & Lee, H. S. (2014) · Journal of Pathology and Translational Medicine · doi:10.4132/koreanjpathol.2014.48.1.36 · Cited by 71
CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification
Pilati, C., Taïeb, J., Balogoun, R., Marisa, L., de Reyniès, A., & Laurent‐Puig, P. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx066 · Cited by 72
Self-citationIbrahim, S., Dakik, H., Vandier, C., Chautard, R., Paintaud, G., Mazurier, F., Lecomte, T., Guéguinou, M., & Raoul, W. (2019) · Cancers · doi:10.3390/cancers11040561 · Cited by 71
ROCK2 inhibition triggers the collective invasion of colorectal adenocarcinomas
Libanje, F., Raingeaud, J., Luan, R., Thomas, Z. A., Zajac, O., Veiga, J., Marisa, L., Adam, J., Boige, V., Malka, D., et al. (2019) · The EMBO Journal · doi:10.15252/embj.201899299 · Cited by 71
Self-citationBrennan, K., Koenig, J. L., Gentles, A. J., Sunwoo, J. B., & Gevaert, O. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.02.025 · Cited by 72
Hentzen, J. E. K. R., Rovers, K. P. B., Kuipers, H., van der Plas, W. Y., Been, L. B., Hoogwater, F. J. H., van Ginkel, R. J., Hemmer, P. H. J., van Dam, G. M., de Hingh, I. H. J. T., et al. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07294-y · Cited by 70
Rosa, M. D., Rega, D., Costabile, V., Duraturo, F., Niglio, A., Izzo, P., Pace, U., & Delrio, P. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16659790 · Cited by 69
Li, Y., Huang, S., Li, Y., Zhang, W., He, K., Zhao, M., Lin, H., Li, D., Zhang, H., Zheng, Z., et al. (2016) · Tumor Biology · doi:10.1007/s13277-016-5254-0 · Cited by 69
Intratumor CMS heterogeneity impacts patient prognosis in localized colon cancer
Marisa, L., Blum, Y., Taieb, J., Ayadi, M., Pilati, C., Le Malicot, K., Lepage, C., Salazar, R., Aust, D., Duval, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0529 · Cited by 68
Self-citationMulti-level gene/MiRNA feature selection using deep belief nets and active learning
Ibrahim, R., Yousri, N. A., Ismail, M. A., & El-Makky, N. M. (2014) · 2014 36th Annual International Conference of the IEEE Engineering in Medicine and Biology Society · doi:10.1109/embc.2014.6944490 · Cited by 68
Zheng, X., Ma, Y., Bai, Y., Huang, T., Lv, X., Deng, J., Wang, Z., Lian, W., Tong, Y., Zhang, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.984480 · Cited by 68
Peng, Y., Miao, H., Wu, S., Yang, W., Zhang, Y., Xie, G., Xie, X., Li, J., Shi, C., Ye, L., et al. (2016) · Autophagy · doi:10.1080/15548627.2016.1217380 · Cited by 68
Bustos, V., Nolan, Á. M., Nijhuis, A. M., Harvey, H. M., Parker, A., Poulsom, R., McBryan, J., Thomas, W., Silver, A. R., & Harvey, B. J. (2017) · Oncotarget · doi:10.18632/oncotarget.20653 · Cited by 68
Chen, J., Na, R., Xiao, C. W., Wang, X., Wang, Y., Yan, D., Song, G., Liu, X., Chen, J., Lu, H., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01815-4 · Cited by 68
Comprehensive Analysis of the Expression and Prognosis for MMPs in Human Colorectal Cancer
Yu, J., He, Z., He, X., Luo, Z., Lian, L., Wu, B., Lan, P., & Chen, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.771099 · Cited by 67
Microenvironmental control of stem cell fate in intestinal homeostasis and disease
Biswas, S., Davis, H., Irshad, S., Sandberg, T., Worthley, D., & Leedham, S. (2015) · The Journal of Pathology · doi:10.1002/path.4563 · Cited by 66
FOXC2 promotes vasculogenic mimicry and resistance to anti-angiogenic therapy
Cannell, I. G., Sawicka, K., Pearsall, I., Wild, S. A., Deighton, L., Pearsall, S. M., Lerda, G., Joud, F., Khan, S., Bruna, A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112791 · Cited by 66
Nanotechnologies for the treatment of colon cancer: From old drugs to new hope
Kotelevets, L., Chastre, E., Desmaële, D., & Couvreur, P. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.06.005 · Cited by 66
Opposing roles of the aldo-keto reductases AKR1B1 and AKR1B10 in colorectal cancer
Taşkoparan, B., Seza, E. G., Canlı, S. D., Tunçer, S., Štefek, M., Gure, A. O., & Banerjee, S. (2017) · Cellular Oncology · doi:10.1007/s13402-017-0351-7 · Cited by 66
Zeb2 drives invasive and microbiota-dependent colon carcinoma
Slowicka, K., Πέττα, Ι., Blancke, G., Hoste, E., Dumas, E., Sze, M., Vikkula, H., Radaelli, E., Haigh, J. J., Jonckheere, S., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0070-2 · Cited by 67
Alderdice, M., Richman, S. D., Gollins, S., Stewart, J. P., Hurt, C., Adams, R., McCorry, A. M., Roddy, A. C., Vimalachandran, D., Isella, C., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5051 · Cited by 65
Advani, S. M., Advani, P., DeSantis, S. M., Brown, D., VonVille, H. M., Lam, M., Loree, J. M., Mehrvarz Sarshekeh, A., Bressler, J., Lopez, D. S., et al. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.07.008 · Cited by 65
Becht, E., Giraldo, N. A., Beuselinck, B., Job, S., Marisa, L., Vano, Y., Oudard, S., Zucman-Rossi, J., Laurent-Puig, P., Sautès-Fridman, C., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1049804 · Cited by 64
Self-citationPicco, G., Petti, C., Centonze, A., Torchiaro, E., Crisafulli, G., Novara, L., Acquaviva, A., Bardelli, A., & Medico, E. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201606773 · Cited by 64
Itraconazole targets cell cycle heterogeneity in colorectal cancer
Buczacki, S. J. A., Popova, S., Biggs, E., Koukorava, C., Buzzelli, J., Vermeulen, L., Hazelwood, L., Francies, H., Garnett, M. J., & Winton, D. J. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171385 · Cited by 64
Long non-coding RNA LINC01296 is a potential prognostic biomarker in patients with colorectal cancer
Qiu, J., & Yan, J. (2015) · Tumor Biology · doi:10.1007/s13277-015-3448-5 · Cited by 64
Chen, H., Xu, J., Hong, J., Tang, R., Zhang, X., & Fang, J. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.010 · Cited by 64
Qureshi-Baig, K., Ullmann, P., Rodriguez, F., Frasquilho, S., Nazarov, P. V., Haan, S., & Letellier, E. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146052 · Cited by 65
Ullmann, P., Qureshi-Baig, K., Rodriguez, F., Ginolhac, A., Nonnenmacher, Y., Ternes, D., Weiler, J., Gäbler, K., Bahlawane, C., Hiller, K., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11772 · Cited by 64
Machine Learning-Based State-of-the-Art Methods for the Classification of RNA-Seq Data
Jabeen, A., Ahmad, N., & Raza, K. (2017) · Lecture notes in computational vision and biomechanics · doi:10.1007/978-3-319-65981-7_6 · Cited by 64
Personalized Medicine—Current and Emerging Predictive and Prognostic Biomarkers in Colorectal Cancer
Koulis, C., Yap, R. J., Engel, R. M., Jardé, T., Wilkins, S., Solon, J. G., Shapiro, J. D., Abud, H. E., & McMurrick, P. J. (2020) · Cancers · doi:10.3390/cancers12040812 · Cited by 66
RBMS1 Suppresses Colon Cancer Metastasis through Targeted Stabilization of Its mRNA Regulon
Yu, J. X., Navickas, A., Asgharian, H., Culbertson, B., Fish, L., Garcia, K., Olegario, J. P., Dermit, M., Dodel, M., Hänisch, B., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1375 · Cited by 64
Chou, J., Kaller, M., Jaeckel, S., Rokavec, M., & Hermeking, H. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01581-1 · Cited by 64
Soundararajan, R., Maurin, M. M., Rodriguez-Silva, J. A., Upadhyay, G., Alden, A. J., Gowda, S. G. B., Schell, M. J., Yang, M., Levine, N. J., Gowda, D., et al. (2024) · Gut · doi:10.1136/gutjnl-2024-332535 · Cited by 63
Iskit, S., Schlicker, A., Wessels, L. F. A., & Peeper, D. S. (2015) · Oncotarget · doi:10.18632/oncotarget.6454 · Cited by 63
Consensus molecular subtypes of colorectal cancer in clinical practice: A translational approach
Valenzuela, G., Canepa, J., Simonetti, C., de Zaldívar, L. S., Marcelain, K., & González‐Montero, J. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i11.1000 · Cited by 63
Piskol, R., Huw, L., Sergin, I., Kljin, C., Modrusan, Z., Kim, D., Kljavin, N., Tam, R., Patel, R., Burton, J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3032 · Cited by 62
“Reclassification of AMC, MVRM, and CIT samples as well as novel classification of our NanoString data was performed for the value of the regularization parameter (l) that gave a minimum mean cross-validated error.”
BackgroundMethodInfluentialTumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage
Glaire, M. A., Domingo, E., Sveen, A., Bruun, J., Nesbakken, A., Nicholson, G., Novelli, M. R., Lawson, K., Oukrif, D., Kildal, W., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0540-4 · Cited by 64
Rap1 regulates hematopoietic stem cell survival and affects oncogenesis and response to chemotherapy
Khattar, E., Maung, K. Z. Y., Chew, C. L., Ghosh, A., Mok, M. M. H., Lee, P., Zhang, J., Chor, W. H. J., Cildir, G., Wang, C. Q., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13082-9 · Cited by 62
BCL9/9L-β-catenin Signaling is Associated With Poor Outcome in Colorectal Cancer
Moor, A. E., Anderle, P., Cantù, C., Rodriguez, P., Wiedemann, N., Baruthio, F., Deka, J., André, S., Valenta, T., Moor, M. B., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.10.030 · Cited by 61
Solé, L., Lobo-Jarne, T., Álvarez-Villanueva, D., Alonso-Marañón, J., Guillén, Y., Guix, M., Sangrador, I., Rozalén, C., Vert, A., Barbachano, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30382-9 · Cited by 60
Martinez-Ordoñez, A., Duran, A., Ruiz-Martinez, M., Cid-Diaz, T., Zhang, X., Han, Q., Kinoshita, H., Muta, Y., Linares, J. F., Kasashima, H., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2022.11.016 · Cited by 60
Zhou, R., Zeng, D., Zhang, J., Sun, H., Wu, J., Li, N., Li, L., Shi, M., Bin, J., Liao, Y., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.043 · Cited by 60
Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer
Graham, D. M., Coyle, V. M., Kennedy, R. D., & Wilson, R. H. (2016) · Current Colorectal Cancer Reports · doi:10.1007/s11888-016-0312-y · Cited by 60
Serrated Colorectal Cancer: The Road Less Travelled?
Nakanishi, Y., Díaz-Meco, M. T., & Moscat, J. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.09.004 · Cited by 60
Gonçalves-Ribeiro, S., Díaz-Maroto, N. G., Berdiel-Acer, M., Soriano, A., Guardiola, J., Martínez-Villacampa, M., Salazar, R., Capellà, G., Villanueva, A., Martínez-Balibrea, E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11121 · Cited by 59
Tobin, N. P., Foukakis, T., Petris, L. D., & Bergh, J. C. S. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12429 · Cited by 59
Up-regulated NRIP2 in colorectal cancer initiating cells modulates the Wnt pathway by targeting RORβ
Wen, Z., Pan, T., Yang, S., Liu, J., Tao, H., Zhao, Y., Xu, D., Shao, W., Wu, J., Liu, X., et al. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0590-2 · Cited by 59
Colorectal cancer subtypes: Translation to routine clinical pathology
Roseweir, A. K., McMillan, D. C., Horgan, P. G., & Edwards, J. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.04.006 · Cited by 60
Yoo, S.-Y., Park, H. E., Kim, J. H., Wen, X., Jeong, S., Cho, N.-Y., Gwon, H. G., Kim, K., Lee, H. S., Jeong, S.-Y., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1159 · Cited by 58
High expression of WISP1 in colon cancer is associated with apoptosis, invasion and poor prognosis
Wu, J., Long, Z., Cai, H., Du, C., Liu, X., Yu, S., & Wang, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.10486 · Cited by 58
Potential Impact of ALKBH5 and YTHDF1 on Tumor Immunity in Colon Adenocarcinoma
Yan, G., An, Y., Xu, B., Wang, N., Sun, X., & Sun, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.670490 · Cited by 58
Integrated multi-omics characterization of KRAS mutant colorectal cancer
Chong, W., Zhu, X., Ren, H., Ye, C., Xu, K., Wang, Z., Jia, S., Shang, L., Li, L., & Chen, H. (2022) · Theranostics · doi:10.7150/thno.73089 · Cited by 58
for the Colon Cancer Family Registry, Shiovitz, S., Copeland, W. K., Passarelli, M. N., Burnett‐Hartman, A. N., Grady, W. M., Potter, J. D., Gallinger, S., Buchanan, D. D., Rosty, C., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.309 · Cited by 58
Disruption of sialic acid metabolism drives tumor growth by augmenting CD8+ T cell apoptosis
Cornelissen, L. A. M., Blanas, A., van der Horst, J. C., Kruijssen, L. J. W., Zaal, A., O’Toole, T. G., Wiercx, L., van Kooyk, Y., & van Vliet, S. J. (2019) · International Journal of Cancer · doi:10.1002/ijc.32084 · Cited by 58
Methylation-Based Therapies for Colorectal Cancer
Cervena, K., Siskova, A., Buchler, T., Vodicka, P., & Vymetalkova, V. (2020) · Cells · doi:10.3390/cells9061540 · Cited by 57
Tumor suppressor miR-215 counteracts hypoxia-induced colon cancer stem cell activity
Ullmann, P., Nurmik, M., Schmitz, M., Rodriguez, F., Weiler, J., Qureshi-Baig, K., Felten, P., Nazarov, P. V., Nicot, N., Zuegel, N., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.02.030 · Cited by 57
Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice
Ragusa, S., Prat-Luri, B., González-Loyola, A., Nassiri, S., Squadrito, M. L., Guichard, A., Cavin, S., Gjorevski, N., Barras, D., Marra, G., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129558 · Cited by 56
“To further study the clinical relevance of these observations, we analyzed the association of PROX1 with clinical outcomes in 444 patients from a prognostically annotated CRC gene expression data set (Gene Expression Omnibus [GEO] GSE39582) (30).”
Classification of gene signatures for their information value and functional redundancy
Cantini, L., Calzone, L., Martignetti, L., Rydenfelt, M., Blüthgen, N., Barillot, E., & Zinovyev, A. (2017) · npj Systems Biology and Applications · doi:10.1038/s41540-017-0038-8 · Cited by 56
He, Z., Lin, J., Chen, C., Chen, Y., Yang, S., Cai, X., He, Y., & Liu, S. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.973 · Cited by 56
Cancer-associated fibroblasts as target and tool in cancer therapeutics and diagnostics
Vlieghere, E. D., Verset, L., Demetter, P., Bracke, M., & Wever, O. D. (2015) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-015-1818-4 · Cited by 57
Pan, Y.-L., Cao, F., Guo, A., Chang, W., Chen, X., Ma, W., Gao, X., Guo, S., Fu, C., & Zhu, J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.260 · Cited by 56
Chida, S., Okayama, H., Noda, M., Saito, K., Nakajima, T., Aoto, K., Hayase, S., Momma, T., Ohki, S., Kono, K., et al. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw069 · Cited by 56
Liu, R., Zhang, W., Liu, Z., & Zhou, H. (2017) · BMC Genomics · doi:10.1186/s12864-017-3761-z · Cited by 56
The Cdx2 homeobox gene suppresses intestinal tumorigenesis through non–cell-autonomous mechanisms
Balbinot, C., Armant, O., Elarouci, N., Marisa, L., Martin, E., Clara, E. D., Onéa, A., Deschamps, J., Beck, F., Freund, J., et al. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20170934 · Cited by 56
Self-citationFessler, E., Jansen, M., De Sousa E Melo, F., Zhao, L., Prasetyanti, P. R., Rodermond, H., Kandimalla, R., Linnekamp, J. F., Franitza, M., van Hooff, S. R., et al. (2016) · Oncogene · doi:10.1038/onc.2016.134 · Cited by 55
TNF‐α promotes invasive growth through the MET signaling pathway
Bigatto, V., Bacco, F. D., Casanova, E., Reato, G., Lanzetti, L., Isella, C., Sarotto, I., Comoglio, P. M., & Boccaccio, C. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.09.002 · Cited by 55
Genomic and transcriptomic heterogeneity of colorectal tumours arising in Lynch syndrome
Binder, H., Hopp, L., Schweiger, M. R., Hoffmann, S., Jühling, F., Kerick, M., Timmermann, B., Siebert, S., Grimm, C., Nersisyan, L., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4948 · Cited by 55
Alwers, E., Jia, M., Kloor, M., Bläker, H., Brenner, H., & Hoffmeister, M. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.12.038 · Cited by 55
Cherradi, S., Martineau, P., Gongora, C., & Rio, M. D. (2019) · Cancer Management and Research · doi:10.2147/cmar.s188192 · Cited by 55
Chen, Y., Hong, W., Liu, M., Guo, X., Yu, Y., Cui, Y., Liu, T., & Liang, L. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04692-1 · Cited by 54
Comprehensive characterization of tumor microenvironment in colorectal cancer via molecular analysis
Wu, X., Yan, H., Qiu, M., Qu, X., Wang, J., Xu, S., Zheng, Y., Ge, M., Yan, L., & Li, L. (2023) · eLife · doi:10.7554/elife.86032 · Cited by 54
Principles of Molecular Utility for CMS Classification in Colorectal Cancer Management
Rejali, L., Asl, R. S., Sanjabi, F., Fatemi, N., Aghdaei, H. A., Niasar, M. S., Moghadam, P. K., Mojarad, E. N., Mini, E., & Nobili, S. (2023) · Cancers · doi:10.3390/cancers15102746 · Cited by 54
Di, Y., Zhang, X., Wen, X., Qin, J., Ye, L., Wang, Y., Song, M. L., Wang, Z., & He, W. (2024) · Advanced Science · doi:10.1002/advs.202402795 · Cited by 54
Classification of Colorectal Cancer in Molecular Subtypes by Immunohistochemistry
ten Hoorn, S., Trinh, A., de Jong, J., Koens, L., & Vermeulen, L. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7765-9_11 · Cited by 56
Subtyping of microsatellite instability-high colorectal cancer
Hu, W., Yang, Y., Qi, L., Chen, J., Ge, W., & Zheng, S. S. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0397-4 · Cited by 56
Colorectal Cancer: The Contribution of CXCL12 and Its Receptors CXCR4 and CXCR7
Goïta, A. A., & Guénot, D. (2022) · Cancers · doi:10.3390/cancers14071810 · Cited by 54
Marzi, L., Combes, E., Vié, N., Ayrolles-Torro, A., Tosi, D., Desigaud, D., Perez-Gracia, E., Larbouret, C., Montagut, C., Iglesias, M., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.313 · Cited by 53
Wang, J., Shibayama, Y., Zhang, A., Ohsaki, H., Asano, E., Suzuki, Y., Kushida, Y., Kobara, H., Masaki, T., Wang, Z., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0350-0 · Cited by 53
Zhang, J., Ying, Y., Li, M., Wang, M., Huang, X., Jia, M., Zeng, J., Ma, C., Zhang, Y., Li, C., et al. (2020) · Theranostics · doi:10.7150/thno.47081 · Cited by 53
Escape from oncogene-induced senescence is controlled by POU2F2 and memorized by chromatin scars
Martínez‐Zamudio, R. I., Stefa, A., de Freitas, J. A. N. L. F., Vasilopoulos, T., Simpson, M., Doré, G. R. G., Roux, P., Galan, M. A., Chokshi, R. J., Bischof, O., et al. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100293 · Cited by 52
Bacterial lipopolysaccharide modulates immune response in the colorectal tumor microenvironment
Sulit, A. K., Daigneault, M. C., Allen‐Vercoe, E., Silander, O., Hock, B. D., McKenzie, J., Pearson, J. F., Frizelle, F., Schmeier, S., & Purcell, R. V. (2023) · npj Biofilms and Microbiomes · doi:10.1038/s41522-023-00429-w · Cited by 52
Bradley, C. A., Dunne, P. D., Bingham, V., McQuaid, S., Khawaja, H. A., Craig, S. G., James, J., Moore, W., McArt, D. G., Lawler, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12933 · Cited by 52
Cumulative prognostic power of laminin genes in colorectal cancer
Galatenko, V., Maltseva, D. V., Galatenko, A. V., Rodin, S., & Tonevitsky, A. (2018) · BMC Medical Genomics · doi:10.1186/s12920-018-0332-3 · Cited by 52
Kandimalla, R., Ozawa, T., Gao, F., Wang, X., Goel, A., Nozawa, H., Hata, K., Nagata, H., Okada, S., Watanabe, T., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.02.027 · Cited by 52
Sun, S., Hang, T., Zhang, B., Zhu, L. W., Wu, Y., Lv, X., Huang, Q., & Yao, H. (2019) · PubMed · Cited by 51
SPP1 macrophages in colorectal cancer: Markers of malignancy and promising therapeutic targets
Xie, Z., Zheng, G., Niu, L., Du, K., Li, R., Dan, H., Duan, L., Wu, H., Ren, G., Dou, X., et al. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101340 · Cited by 51
Wild-type APC predicts poor prognosis in microsatellite-stable proximal colon cancer
Jorissen, R. N., Christie, M., Mouradov, D., Sakthianandeswaren, A., Li, S., Love, C. G., Xu, Z., Molloy, P. L., Jones, I. T., McLaughlin, S., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.296 · Cited by 51
Mutant-Allele Tumor Heterogeneity Scores Correlate With Risk of Metastases in Colon Cancer
Rajput, A., Bocklage, T. J., Greenbaum, A. A., Lee, J., & Ness, S. A. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.11.004 · Cited by 51
Tieng, F. Y. F., Baharudin, R., Abu, N., Yunos, R. I. M., Lee, L., & Mutalib, N. A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00135 · Cited by 51
Chang, Z., Huang, R., Fu, W., Li, J., Ji, G., Huang, J., Shi, W., Yin, H., Wang, W.-F., Meng, T., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00688 · Cited by 53
Aldo Keto Reductases AKR1B1 and AKR1B10 in Cancer: Molecular Mechanisms and Signaling Networks
Banerjee, S. (2021) · Advances in experimental medicine and biology · doi:10.1007/5584_2021_634 · Cited by 51
Evaluating the transcriptional fidelity of cancer models
Peng, D., Gleyzer, R., Tai, W.-H., Kumar, P., Bian, Q., Isaacs, B., da Rocha, E. L., Cai, S., DiNapoli, K. T., Huang, F. W., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00888-w · Cited by 51
Wang, H., Zhang, H., Sun, Z., Chen, W., & Miao, C. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.58135 · Cited by 51
Metadata
- Authors
- Marisa, L., de Reyniès, A., Duval, A., Selves, J., Gaub, M. P., Vescovo, L., Etienne-Grimaldi, M.-C., Schiappa, R., Guenot, D., Ayadi, M., Kirzin, S., Chazal, M., Fléjou, J.-F., Benchimol, D., Berger, A., Lagarde, A., Pencreach, E., Piard, F., Elias, D., Parc, Y., Olschwang, S., Milano, G., Laurent-Puig, P., & Boige, V.
- Affiliations
- Inserm (FR)
- Hôpitaux Universitaires de Strasbourg (FR)
- La Ligue Contre le Cancer (FR)
- Université Toulouse III - Paul Sabatier (FR)
- Centre Hospitalier Universitaire de Nice (FR)
- Hôpital Européen Georges-Pompidou (FR)
- CHU Dijon Bourgogne (FR)
- Institut Gustave Roussy (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- ORCID
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-05-21
- Volume
- 10
- Issue
- 5
- Pages
- e1001453
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC3660251
- OpenAlex
- W2154941270
- Cited by
- 1,507
- References
- 40
- Citations by year
- 2026: 84 · 2025: 111 · 2024: 108 · 2023: 142 · 2022: 145 · 2021: 194 · 2020: 131 · 2019: 126 · 2018: 131 · 2017: 108 · 2016: 90 · 2015: 74 · 2014: 53 · 2013: 8
- FWCI
- 56.08
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- American Association for Cancer Research
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Keywords
- colon cancer, molecular subtypes, gene expression signatures, mismatch repair deficiency, chromosomal instability, KRAS mutation, BRAF mutation, TP53 mutation, CpG island methylator phenotype, Wnt signaling, relapse-free survival, prognosis
- MeSH terms
- Adult, Aged, Aged, 80 and over, Colonic Neoplasms, Female, France, Genetic Testing, Humans, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Staging, Phenotype, Predictive Value of Tests, Prognosis, Risk Factors, RNA, Messenger, Time Factors, Biomarkers, Tumor, Reproducibility of Results, Gene Expression Regulation, Neoplastic, Multivariate Analysis, Cluster Analysis, Chi-Square Distribution, Logistic Models, Proportional Hazards Models, Risk Assessment, Genetic Predisposition to Disease, Gene Expression Profiling, Kaplan-Meier Estimate, Young Adult, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.